Platelet-derived growth factor receptors: A therapeutic target in solid tumors

Seminars in Oncology

Volumn 28, Issue 5 SUPPL. 17, 2001, Pages 27-33

  George, Daniel ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG APPROVAL; DRUG INDICATION; DRUG RESPONSE; GLIOBLASTOMA; HUMAN; METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 0035207172     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(01)90100-9     Document Type: Review

References (32)

1. cDNA sequence and chromosomal localization of human plateletderived growth factor A-chain and its expression in tumor cell lines
2. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor
3. SH2 and SH3 domains: Elements that control interactions of cytoplasmic signaling proteins
4. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors
5. Activation of phosphoinositide 3-kinase is required for PDGF-stimulated membrane ruffling
6. Membrane ruffling and chemotaxis transduced by the PDGF beta-receptor require the binding site for phosphatidylinositol 3′ kinase
7. Ras-like GTPases
8. Polypeptide growth factors: Roles in normal and abnormal cell growth
9. Involvement of platelet-derived growth factor in disease: Development of specific antagonists
10. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors
11. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop
12. Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops
13. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways
14. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein
15. Virocrine transformation: The intersection between viral transforming proteins and cellular signal transduction pathways
16. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors
17. Chimaeric analysis reveals role of PDGF receptors in all muscle lineages
18. C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice
19. Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor α and β receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas
20. Platelet-derived growth factor A and B chains and the α and β receptors in prostatic intraepithelial neoplasia
21. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor
22. A multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer
23. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
24. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
25. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
26. Abl proteintyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors
27. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia
28. Activity of a specific inhibitor of BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
29. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
30. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (Pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD117)
31. STI571, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC phase I study
32. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer